CHAPTER 1 - MARKET SUMMARY
Market Overview
The UAE Artificial Intelligence in Oncology Market covers commercial software, AI-attributable medical technology and implementation services used for cancer diagnosis, treatment planning, genomic interpretation and patient monitoring. Independent international cancer statistics indicate 5,526 new cancer cases in the UAE in 2022. The economic opportunity arises from repeated screening, diagnostic and treatment interactions, rather than incident cases alone.
Abu Dhabi represents the principal commercial cluster, accounting for an estimated 55% of UAE oncology AI revenue in 2024 in the supplied market model. Its concentration of specialized hospitals, genomics infrastructure and public healthcare procurement provides implementation scale. In March 2025, Lunit announced a five-year agreement with SEHA, covering a network of 14 hospitals and more than 70 clinics.
Market Value
USD 19 million
2025
Dominant Region
Abu Dhabi
2025
Dominant Segment
Cancer Diagnostics and Imaging AI
2025
Total Number of Players
38
2024 estimated vendor universe
Future Outlook
The UAE Artificial Intelligence in Oncology Market is projected to reach USD 82 million in 2031 and USD 105 million in 2032, compared with USD 19 million in 2025. The central forecast assumes a 28.0% CAGR during 2025-2032, following estimated historical growth of 19.8% during 2020-2025. The principal expansion mechanism is increasing commercial value per integrated oncology workflow, supported by broader software functionality, precision medicine contracts and enterprise deployment. This outlook extends the supplied market calculator's base scenario beyond its original horizon and remains conditional on procurement, regulatory clearance and clinical validation.
Revenue composition is expected to evolve as healthcare organizations connect imaging systems, pathology platforms, genomic databases and oncology information systems. The highest growth potential is associated with drug discovery AI and precision oncology, although imaging remains important for clinical deployment volume. Public health networks provide early adoption scale, while private hospitals create opportunities for differentiated diagnostics and premium care delivery. Investors should evaluate recurring software revenue, clinical evidence, implementation costs and contract concentration separately. Changes in reimbursement arrangements, data governance or AI medical device regulation could materially alter realized adoption and supplier margins.
28.0%
Forecast CAGR
USD 105 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR (2020-2025)
19.8%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage this market analysis for investment, strategy and operational planning.
Investors
Segment CAGR, recurring revenue, clinical validation, investment risk
Corporates
Procurement economics, software positioning, partnerships, customer acquisition, retention
Government
Screening coverage, medical device regulation, interoperability, patient safety
Operators
Clinical workflow, diagnostic throughput, deployment costs, quality assurance
Financial institutions
Contract stability, financing requirements, revenue visibility, borrower risk
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates historical market size, year-over-year growth dynamics and forecast projections supported by commercial adoption, clinical infrastructure, oncology software monetization and sector-specific demand indicators.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance
During 2020-2025, the market progressed from selective clinical applications to broader hospital deployment and genomics-enabled healthcare investment. The historical modeled series has its lowest annual value in 2020, followed by an estimated 22.0% expansion in 2023 and further growth in 2024. The historical CAGR of 19.8% for 2020-2025 captures early digital adoption and rising commercial contract complexity. The transition from proof-of-concept projects toward longer-term clinical agreements is important because recurring licenses generate more predictable vendor cash flows than isolated pilot contracts.
Forecast Market Outlook
During 2025-2032, the modeled forecast CAGR of 28.0% reflects a sustained expansion in oncology-focused software deployment, integration services and AI-assisted clinical analytics. Annual revenue growth is expected to depend more heavily on contract monetization and scope expansion than on clinical procedure volume alone. The forecast includes applications that can improve diagnostic prioritization, assist tumor characterization, support genomic interpretation and automate elements of radiotherapy planning. Commercial realization will depend on validated clinical performance, procurement decisions, data governance compliance and evidence of measurable operational savings.
CAGR Value
28.00% (Forecast Period 2025-2032).
CHAPTER 5 - Market Data
Market Breakdown
The UAE oncology AI revenue model combines diagnostic workload, technology adoption and increasing commercial value per integrated clinical workflow. The following market indicators are modeled estimates, not independently published annual statistics.
Year | Market Size (USD Mn) | YoY Growth (%) | Procedure-Equivalent Volume (000s) | AI Screening Adoption (%) | Blended Revenue Intensity (USD per Procedure-Equivalent) | Period |
|---|---|---|---|---|---|---|
| 2020 | $8 Mn | +0.0% | 121 | 25% | Forecast | |
| 2021 | $9 Mn | +13.2% | 127 | 29% | Forecast | |
| 2022 | $10 Mn | +16.3% | 133 | 33% | Forecast | |
| 2023 | $12 Mn | +22.0% | 140 | 37% | Forecast | |
| 2024 | $15 Mn | +19.9% | 147 | 42% | Forecast | |
| 2025 | $19 Mn | +28.0% | 154 | 46% | Forecast | |
| 2026 | $24 Mn | +28.0% | 162 | 50% | Forecast | |
| 2027 | $31 Mn | +28.0% | 170 | 55% | Forecast | |
| 2028 | $39 Mn | +28.0% | 178 | 60% | Forecast | |
| 2029 | $50 Mn | +28.0% | 187 | 65% | Forecast | |
| 2030 | $64 Mn | +28.0% | 197 | 70% | Forecast | |
| 2031 | $82 Mn | +28.0% | 207 | 74% | Forecast | |
| 2032 | $105 Mn | +28.0% | 217 | 78% | Forecast |
Procedure-Equivalent Volume
154,000 modeled units (2025, UAE). This normalized volume benchmark helps evaluate how revenue expands relative to selected diagnostic workflows. Lunit's five-year SEHA agreement anticipates analysis of more than 100,000 mammograms across the contract period, demonstrating a real institutional use case, but not establishing the modeled nationwide volume figure.
AI Screening Adoption
46% modeled penetration (2025, UAE). Adoption is an analytical proxy representing selected addressable diagnostic facilities rather than all national hospitals. Emirates Health Services reported AI-supported mammography deployment across nine facilities in 2024, illustrating the commercial relevance of broader clinical screening adoption.
Blended Revenue Intensity
USD 122 per procedure-equivalent (2025, UAE model). This market-wide normalization reflects subscription, integration and AI-attributable revenue, not a quoted clinical fee. M42's announced integration of clinical and genomic data with Oracle Health illustrates why enterprise functionality can raise contract value beyond isolated imaging interpretation.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across seven commercially relevant dimensions providing insights into solution economics, oncology applications, customer purchasing structures, disease-specific demand and technology adoption.
No of Segments
7
Dominant Segment
Solution Type
Fastest Growing Segment
Application
Solution Type
Application
Disease Area
End User
Geography
Technology
Revenue Model
Key Segmentation Takeaways
Comprehensive analysis across all seven segmentation dimensions indicates that commercial value is concentrated in specialized software, clinical workflow integration and institutional purchasing. These segmentation dimensions are independent analytical views of one market; their values must not be added together across dimensions.
Solution Type
Software Solutions is the largest underlying category because imaging interpretation, genomic analytics and hospital decision-support functions can generate recurring licensing revenue. Implementation Services remains commercially important because adoption requires integration with imaging archives, electronic health records, pathology systems and clinical reporting workflows. AI-Enabled Hardware represents the attributable intelligence component of medical equipment rather than the value of an entire scanner or radiotherapy system.
Application
Drug Discovery and Development AI is the fastest-growing modeled application during 2025-2032, supported by target discovery, generative chemistry and early-stage pharmaceutical research. Precision Oncology and Genomics is expected to become increasingly important as health systems connect genomic and clinical datasets. Cancer Diagnostics and Imaging AI remains the principal near-term deployment category because screening and radiology workflows have identifiable operational demand and clinical validation pathways.
CHAPTER 7 - Regional Analysis
Regional Analysis
The UAE ranks second in the selected six-country Gulf peer comparison under the report's narrow domestic commercial oncology AI revenue definition. Saudi Arabia benefits from a larger cancer caseload, while the UAE benefits from concentrated healthcare technology investment, advanced clinical infrastructure and specialist procurement networks. Peer market figures are modeled directional comparisons rather than standardized independently audited country statistics.
Focus Country Ranking
2nd of 6 selected countries (2025 modeled)
Focus Country Market Size
USD 19 Mn (2025)
UAE Forecast CAGR (2025-2032)
28.0%
Focus Country Ranking
2nd of 6 selected countries (2025 modeled)
Focus Country Market Size
USD 19 Mn (2025)
UAE Forecast CAGR (2025-2032)
28.0%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | Saudi Arabia | United Arab Emirates | Kuwait | Qatar | Oman | Bahrain |
|---|---|---|---|---|---|---|
| Market Size (USD Mn, 2025) | 31 | 19 | 12 | 8 | 7 | 4 |
| Forecast CAGR (2025-2032) | 25.5% | 28.0% | 24.0% | 27.0% | 23.0% | 22.0% |
Market Position
The UAE's modeled second-place ranking reflects concentrated spending on advanced clinical AI despite its smaller annual cancer caseload than Saudi Arabia. The UAE recorded 5,526 new cases in 2022.
Growth Advantage
The UAE's modeled 28.0% CAGR during 2025-2032 exceeds Saudi Arabia's modeled 25.5% and Kuwait's 24.0%, reflecting assumptions about enterprise software monetization, genomics infrastructure and clinical AI procurement.
Competitive Strengths
The UAE combines government-linked procurement, specialist oncology facilities and local data infrastructure. The 2025 Lunit-SEHA agreement spans 14 hospitals, demonstrating the ability to scale commercial imaging AI across institutions.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the UAE Artificial Intelligence in Oncology Market, including cancer screening demand, technology validation, public procurement, regulatory compliance and the commercialization of precision medicine.
Growth Drivers
Expansion of AI-Assisted Cancer Screening
- SEHA's five-year mammography AI agreement (2025, UAE) demonstrates the transition from evaluation to recurring deployment, creating commercial opportunities for licensing, support and workflow analytics.
- Emirates Health Services reported an AI-assisted breast screening initiative covering nine hospitals and health centers (2024, UAE), indicating that diagnostic AI can be deployed across a distributed provider network rather than only in tertiary hospitals.
- National cancer incidence of 5,526 new cases (2022, UAE) supports continuing demand for diagnosis and follow-up, while screening of unaffected populations creates a wider addressable workflow than incident cases alone.
Precision Medicine and Clinical Data Integration
- The 2026 M42 data intelligence initiative (UAE) seeks to unify genomic, clinical and real-world information, potentially enabling broader clinical decision support and more sophisticated treatment analytics.
- The April 2026 Abu Dhabi Biobank inauguration (UAE) strengthens access to consent-based biological and clinical information for research, creating infrastructure that may support future validated precision oncology applications.
- The October 2026 oncology biobank collaboration (UAE) involving Cleveland Clinic Abu Dhabi establishes a further research pathway connecting cancer samples and clinical information, potentially improving future model development and translational research.
Government-Backed Healthcare Digitalization
- The national AI strategy establishes an institutional framework for public-sector technology adoption, improving the strategic relevance of oncology solutions within healthcare digital transformation through 2031 (UAE).
- The 2025 government health system achievements report (UAE) references national lung cancer early-detection guidance, creating a policy foundation for more structured diagnostic pathways and future digital decision-support applications.
- The 2025 Oracle, Cleveland Clinic and G42 partnership (UAE) demonstrates continued public-private interest in integrated clinical AI platforms, although a strategic partnership should not automatically be treated as realized oncology revenue.
Market Challenges
Medical Device Authorization and Clinical Validation
- Medical device authorization requires product documentation, conformity information and applicable supporting evidence. These requirements create regulatory preparation costs before clinical commercialization, particularly for AI-enabled diagnostic medical devices (UAE regulatory framework).
- The Emirates Drug Establishment operates a separate product-classification process with a published 10-working-day service duration (UAE), making accurate classification a practical prerequisite for budgeting and market access.
- Regulatory authorization does not replace disease-specific clinical validation. Under the five-year SEHA imaging AI agreement (2025, UAE), deployment followed an earlier proof-of-concept evaluation, illustrating the commercial importance of local workflow evidence.
Healthcare Data Governance and Interoperability
- Article 13 of Federal Law No. 2 of 2019 (UAE) restricts storage, processing and transfer of covered health information outside the country except through applicable authorization, affecting foreign cloud architecture and cross-border training arrangements.
- The 2020 executive regulations (UAE) provide additional implementation provisions for electronic health information systems, increasing the need for contract-level technical and legal review.
- Enterprise integration involving clinical, genomic and real-world information, as proposed in 2026 by M42 and Oracle Health, introduces interoperability and data governance complexity that can increase implementation time and supplier support requirements.
Concentrated Procurement and Commercial Evidence Requirements
- Network-wide hospital purchasing can reduce individual vendor selling costs but increase contract concentration. SEHA's 14-hospital network (2025, UAE) illustrates how a small number of organizational purchasing decisions can influence deployment scale.
- Model performance must translate into measurable clinical and operational improvements. The 2024 Emirates Health Services screening initiative (UAE) reported improvements in diagnostic workflow performance, creating a benchmark for evidence-based procurement evaluation.
- Development-stage relationships do not necessarily generate commercial sales. The 2025 Oracle, Cleveland Clinic and G42 announcement included a nonbinding partnership element, emphasizing the importance of distinguishing strategic cooperation from recognized revenue.
Market Opportunities
Commercialization of Precision Oncology Platforms
- Enterprise genomic interpretation can be monetized through subscription contracts and per-case analysis where clinically validated. The 2026 M42 integration initiative indicates a potential distribution pathway through an established healthcare network.
- Clinical laboratories, oncology departments and platform integrators may benefit from disease-specific modules built on the 2026 Abu Dhabi Biobank infrastructure, provided commercial use complies with consent and governance requirements.
- Expansion depends on validated treatment recommendations and reliable integration with hospital records. The October 2026 cancer biobank collaboration strengthens research infrastructure but does not itself establish commercial deployment of any specific oncology algorithm.
AI-Assisted Drug Discovery and Translational Research
- Generative chemistry and target-identification services can create research contract opportunities. Insilico Medicine's Abu Dhabi facility established in 2023 demonstrates an existing local technology development footprint.
- Specialized biotechnology investors can support translational partnerships where contractual economics are linked to research milestones. Insilico's 2026 UAE preclinical candidate announcement illustrates continuing activity in AI-enabled drug development.
- Commercial scale requires successful progression from molecular discovery to validated preclinical and clinical programs. The 2026 UAE drug discovery milestone demonstrates technical progress but does not establish marketed therapeutic revenue.
Expansion into Integrated Hospital Oncology Workflows
- Vendors can integrate imaging, pathology and genomic analytics into hospital workflows instead of selling isolated tools. The 2025 partnership announcement identifies clinical AI and data integration as central technical priorities.
- Hospitals and systems integrators can benefit from reduced fragmentation of clinical information. The September 2026 M42 announcement describes plans to combine longitudinal records and data intelligence, supporting the enterprise integration opportunity.
- Revenue realization depends on deployment completion, data permissions and demonstrated clinical benefits. The 2025 SEHA mammography agreement provides an example of a defined commercial deployment pathway with an identified institutional customer.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market includes sovereign-backed healthcare technology platforms, multinational imaging suppliers, specialized diagnostic AI companies and emerging drug discovery developers. Competition depends on clinical evidence, institutional relationships, integration capabilities and regulatory readiness.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
M42 | - | Abu Dhabi, UAE | 2023 | Precision medicine, genomics and clinical AI infrastructure |
Siemens Healthineers | - | Erlangen, Germany | - | AI-enabled imaging, treatment planning and radiology software |
GE HealthCare | - | Chicago, United States | 2023 | AI-enabled diagnostic imaging and image reconstruction |
Philips | - | Amsterdam, Netherlands | 1891 | Imaging informatics and clinical workflow analytics |
Lunit | - | Seoul, South Korea | 2013 | Mammography AI and cancer diagnostic software |
Oracle Health | - | Austin, United States | - | Enterprise clinical records and precision medicine data integration |
Insilico Medicine | - | - | 2014 | AI-assisted drug discovery and molecular design |
SOPHiA GENETICS | - | - | 2011 | Genomic interpretation and precision oncology analytics |
Roche Diagnostics | - | Basel, Switzerland | - | Molecular diagnostics and digital pathology ecosystem |
Aidoc | - | - | 2016 | Clinical imaging AI and workflow prioritization |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Validated Clinical Workflow Coverage
Average Deployment Implementation Time
Recurring Oncology AI Revenue Growth
Revenue per Active Clinical Site
Analysis Covered
Market Share Analysis:
Evaluates supplier revenue attribution and institutional customer concentration patterns.
Cross Comparison Matrix:
Benchmarks clinical capability, implementation complexity and software monetization performance.
SWOT Analysis:
Assesses technology differentiation, regulatory barriers and strategic commercial exposure.
Pricing Strategy Analysis:
Compares enterprise licenses, procedure fees and implementation contract structures.
Company Profiles:
Reviews core offerings, geographic presence and oncology-specific commercial relevance.
CHAPTER 10 - REPORT TOC
Table of Contents
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Review oncology AI company disclosures
- Assess UAE cancer incidence statistics
- Evaluate clinical imaging deployment announcements
- Map healthcare data protection requirements
Primary Research
- Interview hospital chief medical information officers
- Consult consultant radiologists and oncologists
- Engage medical technology commercialization directors
- Interview genomic laboratory operations managers
Validation and Triangulation
- Design a 200-respondent validation framework
- Reconcile hospital demand and vendor revenue
- Separate commercial deployment from research activity
- Validate clinical use cases against regulations
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
No adjacent reports found.
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals